David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into the role of chronic inflammation in myelodysplastic syndromes (MDS), and the processes that contribute to MDS pathogenesis. Dr Sallman first emphasizes the important role of inflammation in lower-risk MDS, and then goes on to discuss how targeting pathways involved may lead to novel therapeutic strategies, and clinical trials in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.